Drugs / CP-IL22BP mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07583654 | Jul 2026 → Jun 2027 expected | metastatic malignant neoplasm | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-IL22BP mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583654 ↗ |
| Modality | Messenger RNA (mRNA) | “peptide-based IL-22BP mRNA gene therapy” NCT07583654 ↗ |
| Route | Other | “administered via intratumoral injection” NCT07583654 ↗ |